The complaint
The case is Jackson Biotechs, LLC v. Corning Incorporated and Corning Science Mexico, S.A. de C.V., No. 2:26-cv-00985 (E.D. Tex., Marshall Division), filed October 30, 2026, ECF No. 1. The complaint demands a jury trial. Jackson Biotechs, a Texas limited liability company with a mailing address in Murray, Kentucky, asserts U.S. Patent 7,960,168 (the '168 patent) and says it seeks only retrospective relief for qualifying United States infringement occurring within six years before the filing of this action and no later than January 6, 2025. The complaint describes Corning Incorporated as a New York corporation with principal executive offices in Corning, New York, and describes Corning Science Mexico, S.A. de C.V. as a company organized under the laws of Mexico with its manufacturing facility in Reynosa, Tamaulipas, Mexico. It uses the names Corning and Defendants for both companies. (Compl. introduction and paras. 1 to 3.)
Jackson Biotechs filed an earlier complaint on the same patent in the same court, No. 2:26-cv-00842 (E.D. Tex., Marshall Division), on September 18, 2026, against another company. That complaint likewise says the plaintiff seeks only retrospective relief for qualifying United States infringement occurring within six years before the filing of the action and no later than January 6, 2025.
What the patent covers
The complaint says the United States Patent and Trademark Office issued the '168 patent, titled Biologically Active Substance Transfer Sheet, Cell Culture Kit Constituted of Cell Culture Plate and Biologically Active Substance Transfer Sheet, Producing Method Thereof and Method for Screening Cell Culture Conditions Utilizing the Same, on June 14, 2011, from Application No. 12/183,008. It says the patent claims priority to December 16, 2003. It says independent claim 1 recites, among other things, a culture plate having two or more discrete culture regions, a sheet having discrete covering portions corresponding to those regions, a first biologically active substance immobilized on the culture regions, a second biologically active substance attached to the covering portions, a sheet that is elastic or flexible at least at those portions, and use of the sheet to transfer the second substance to the culture regions. It says independent claim 12 recites a method of culturing a cell with a kit defined in claim 1 or specified dependent claims, including covering the culture regions with the sheet's covering portions and contacting a cell with a biologically active substance in a culture liquid in those regions. It says claims 3 through 6 and 8 through 10 add limitations concerning recessed culture regions, wall structures, holding layers, release, and covering-portion structures. Count I, discussed below, names at least claim 1 and at least claim 12. (Compl. paras. 19, 20, 23, and 24.)
The complaint alleges that Jackson Biotechs is the sole owner by a written assignment effective August 22, 2026, which transferred all right, title, and interest, including accrued causes of action and the right to recover damages for infringement occurring before the assignment, and that the assignment was recorded on September 2, 2026, at Reel/Frame 075885/0292. It alleges that the patent is presumed valid under 35 U.S.C. 282 and expired on January 6, 2025. It alleges that Jackson Biotechs has not made, offered for sale, or sold a patented article since acquiring the patent after expiration, and that it seeks only damages legally recoverable under 35 U.S.C. 284 and 286, subject to proof of compliance with or inapplicability of any limitation under 35 U.S.C. 287 during the relevant period. (Compl. paras. 21, 25, and 26.)
What the lawsuit alleges
The complaint identifies the accused instrumentalities as Corning HTS Transwell-96 permeable-support products, including catalog numbers 3374, 3384, and 3392, Corning FluoroBlok 96-Multiwell Insert systems, related BioCoat 96-well migration or invasion systems, corresponding receiver and spheroid plates, including catalog number 4520, and materially similar Corning 96-well common-insert products. It says the names and catalog numbers identify representative instrumentalities and do not exclude materially similar configurations shown by discovery to operate in the same accused manner. It says the allegations are limited to complete configurations and uses that satisfy every asserted claim limitation, and that it does not allege that every sale or every possible use of a component product infringed. (Compl. paras. 27 and 29.)
The complaint alleges that the accused complete configurations use cells attached to the membrane portions as the second biologically active substance and, in the alternative, use membrane-bound fibronectin, collagen, laminin, Matrigel/ECM, or cell-secreted factors. It alleges that the claimed first substance is supplied by complete customer, demonstration, or validation workflows employing an immobilized receiver-well ECM protein, an adsorbed or gel-bound ligand, or an adherent target-cell layer. It points to a 2013 Corning technical bulletin reporting chemotaxis assays in 96-well plates using FluoroBlok inserts, and to a 2019 Corning poster reporting a 96-well Transwell and spheroid co-culture configuration, and it describes the bulletin as pre-expiration evidence of Corning's own use of that architecture. It alleges, on information and belief, that during the relevant period Corning made and used complete accused configurations in the United States for development, validation, quality-control testing, demonstrations, training, and technical support. It alleges that Corning also offered and sold the multiwell systems to United States customers, some of whom used them in the complete coated-receiver workflows alleged. (Compl. paras. 28 and 30 to 32.)
Count I alleges that, during the relevant period, the defendants directly infringed at least claim 1 of the '168 patent under 35 U.S.C. 271(a), literally and/or under the doctrine of equivalents. It alleges that Corning Incorporated made, used, offered to sell, sold, and imported complete accused instrumentalities in the United States, and that Corning Science Mexico imported into the United States, and offered to sell and sold for delivery in the United States, accused instrumentalities that it manufactured in Reynosa in the complete configurations described. It alleges that Corning Incorporated directly infringed at least claim 12 under 35 U.S.C. 271(a), literally and/or under the doctrine of equivalents, by using complete accused instrumentalities in United States research, validation, testing, quality control, demonstrations, training, technical support, and/or commercial services. It alleges that United States customers, laboratories, service providers, and other end users directly infringed at least claims 1 and 12 by assembling and using the complete accused instrumentalities as instructed. It alleges that, where multiple persons participated in an accused method, the steps were attributable to a single entity. (Compl. paras. 41 to 44.)
On manufacture and importation, the complaint alleges that Corning manufactures accused instrumentalities in Mexico and imports them into the United States. It alleges that a laboratory-products distributor lists the country of origin of HTS Transwell-96 catalog numbers 3374, 3380, 3384, and 3392 as Mexico, that other resellers list United States origin for some HTS Transwell-96 units, and that the same distributor lists United States origin for receiver and spheroid plate catalog number 4520. It alleges, on information and belief, that during the relevant period a substantial portion of the HTS Transwell-96 and related 96-well insert products sold in the United States was manufactured in Mexico, that the balance was manufactured by Corning Incorporated in the United States, and that the Mexico-origin accused instrumentalities were manufactured by Corning Science Mexico at its Reynosa plant, at Corning Incorporated's direction and to Corning Incorporated's specifications, for sale in the United States. It alleges, on information and belief, that Corning Science Mexico used the same Reynosa-to-United States channel, with Corning Incorporated as consignee and importer, to export accused instrumentalities throughout the relevant period and before January 6, 2025. It alleges that customs records show Corning Science Mexico manufactures and ships laboratory plasticware in commercial volumes and exports products from Reynosa to Corning Incorporated in the United States, and that a trade-data service reports 2,897 Mexican customs shipment records for Corning Science Mexico, and that United States Customs and Border Protection bill-of-lading data identify Corning Science Mexico as the shipper of hundreds of ocean shipments of "plastic laboratory ware" and "plastic containers with lid for scientific use" through United States ports, including Houston, Texas, Miami, Florida, and New Orleans, Louisiana, between at least October 2013 and July 2026, including shipments in each year from 2015 through 2024, records the complaint says reflect the scale of Corning Science Mexico's laboratory-plasticware manufacturing for Corning's worldwide distribution. (Compl. paras. 35 to 38.)
The complaint alleges that Corning Incorporated, through its Life Sciences segment and related operations, develops, manufactures, markets, sells, and supports cell-culture consumables, permeable supports, migration systems, and related laboratory products in the United States, and that Corning Incorporated reports that it manufactures its Life Sciences products in California, Illinois, Maine, Massachusetts, New York, North Carolina, Utah, Virginia, China, France, Mexico, Brazil, and Poland. It alleges that Corning Science Mexico operates Corning's Life Sciences manufacturing plant in Reynosa, and that in January 2015 the Tamaulipas state government reported that Corning Science Mexico had inaugurated a $9.5 million expansion of the plant, bringing its workforce to 515 employees, that it manufactures and assembles products for the medical sector, including centrifuge tubes, cryogenic tubes, and pipette tips, and that it has operated in Tamaulipas since 1999, exporting its products. It alleges that Corning Incorporated has listed Corning Science Mexico, S.A. de C.V. among its subsidiaries in Exhibit 21 to its Annual Report on Form 10-K, and that the Reynosa plant is registered with the Food and Drug Administration as a medical-device manufacturing establishment under the name Corning Science Mexico, with Corning Incorporated identified as the owner/operator. It alleges, on information and belief, that Corning Incorporated owns, directs, and controls Corning Science Mexico's manufacturing operations, including the manufacture of products for sale in the United States, and that Corning Science Mexico acts as Corning Incorporated's manufacturing arm for those products. (Compl. paras. 2 to 5.)
The complaint alleges subject-matter jurisdiction under 28 U.S.C. 1331 and 1338(a). It alleges specific personal jurisdiction over Corning Incorporated because Corning Incorporated offered for sale, sold, shipped, demonstrated, and supported the accused instrumentalities for customers in Texas and this district, and it alleges, on information and belief, that before January 6, 2025 Corning Incorporated shipped accused 96-well systems into the district. It alleges specific personal jurisdiction over Corning Science Mexico and alleges, on information and belief, that during the relevant period Corning Science Mexico manufactured accused instrumentalities at its Reynosa plant and shipped them by truck into Texas for importation and distribution by Corning Incorporated. It pleads personal jurisdiction under Federal Rule of Civil Procedure 4(k)(2) in the alternative. It alleges that venue is proper as to Corning Incorporated under 28 U.S.C. 1400(b) because Corning Incorporated committed acts of infringement in the district and maintained regular and established places of business there through fixed locations in Plano and McKinney, Texas, and it alleges, on information and belief, that employees regularly worked for Corning Incorporated from fixed locations in those cities. It alleges that venue is proper as to Corning Science Mexico under 28 U.S.C. 1391(c)(3) because Corning Science Mexico is not a resident of the United States. It alleges that joinder is proper under 35 U.S.C. 299(a), and it alleges, on information and belief, that Corning Science Mexico manufactured and exported accused instrumentalities to the United States and that Corning Incorporated imported, offered for sale, and sold them. (Compl. paras. 6 to 16.)
The prayer asks for a judgment that each defendant infringed one or more claims of the '168 patent during the patent term, damages under 35 U.S.C. 284 adequate to compensate for legally recoverable infringement occurring within six years before filing and no later than January 6, 2025, in no event less than a reasonable royalty, pre-judgment and post-judgment interest and costs, and any other retrospective relief authorized by law. (Compl. para. 45 and Prayer.)
What to watch next
Watch for the defendants' answers or other responses, including any challenge to personal jurisdiction or venue. The case can end at any time, including by settlement or voluntary dismissal.